menu
    • menu

    Find Belzutifan manufacturers, exporters & distributors on PharmaCompass

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-20

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    2

    API Suppliers

    API Suppliers

    0

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    0

    EU WC

    EU WC

    0

    KDMF

    KDMF

    0

    NDC API

    NDC API

    0

    VMF

    NDC API

    2

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 0

    MARKET PLACE

    1

    API

    0

    FDF

    0INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    3

    FDF Dossiers

    FDF Dossiers

    1

    FDA Orange Book

    FDA (Orange Book)

    0

    Europe

    Europe

    1

    Canada

    Canada

    1

    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Listed Dossiers

    Listed Dossiers

    7DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    PATENTS & EXCLUSIVITIES

    4

    US Patents

    3

    US Exclusivities

    0

    Health Canada Patents

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    7

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    29,705,807

    Annual Reports

    218

    Finished Drug Prices

    NA

    0RELATED EXCIPIENT COMPANIES

    0EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: Pt2977, 1672668-24-4, Mk-6482, Welireg, Mk6482, Belzutifan [inn]
    Molecular Formula
    C17H12F3NO4S
    Molecular Weight
    383.3  g/mol
    InChI Key
    LOMMPXLFBTZENJ-ZACQAIPSSA-N
    FDA UNII
    7K28NB895L
    Belzutifan
    Belzutifan is an orally active, small molecule inhibitor of hypoxia inducible factor (HIF)-2alpha (HIF-2a), with potential antineoplastic activity. Upon oral administration, belzutifan binds to and blocks the function of HIF-2alpha, thereby preventing HIF-2alpha heterodimerization and its subsequent binding to DNA. This results in decreased transcription and expression of HIF-2alpha downstream target genes, many of which regulate hypoxic signaling. This inhibits cell growth and survival of HIF-2alpha-expressing tumor cells. HIF-2alpha, the alpha subunit for the heterodimeric transcription factor HIF-2, is overexpressed in many cancers and promotes tumorigenesis.
    1 2D Structure

    Belzutifan

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    3-[[(1S,2S,3R)-2,3-difluoro-1-hydroxy-7-methylsulfonyl-2,3-dihydro-1H-inden-4-yl]oxy]-5-fluorobenzonitrile
    2.1.2 InChI
    InChI=1S/C17H12F3NO4S/c1-26(23,24)12-3-2-11(13-14(12)17(22)16(20)15(13)19)25-10-5-8(7-21)4-9(18)6-10/h2-6,15-17,22H,1H3/t15-,16-,17+/m1/s1
    2.1.3 InChI Key
    LOMMPXLFBTZENJ-ZACQAIPSSA-N
    2.1.4 Canonical SMILES
    CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O
    2.1.5 Isomeric SMILES
    CS(=O)(=O)C1=C2[C@@H]([C@@H]([C@@H](C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O
    2.2 Other Identifiers
    2.2.1 UNII
    7K28NB895L
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 3-(((1s,2s,3r)-2,3-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1h-inden-4-yl)oxy)-5-fluorobenzonitrile

    2. Mk-6482

    3. Mk6482

    4. Pt-2977

    5. Pt2977

    6. Welireg

    2.3.2 Depositor-Supplied Synonyms

    1. Pt2977

    2. 1672668-24-4

    3. Mk-6482

    4. Welireg

    5. Mk6482

    6. Belzutifan [inn]

    7. Belzutifan [usan]

    8. Pt-2977

    9. 3-(((1s,2s,3r)-2,3-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1h-inden-4-yl)oxy)-5-fluorobenzonitrile

    10. 7k28nb895l

    11. 3-[[(1s,2s,3r)-2,3-difluoro-1-hydroxy-7-methylsulfonyl-2,3-dihydro-1h-inden-4-yl]oxy]-5-fluorobenzonitrile

    12. 3-{[(1s,2s,3r)-2,3-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1h-inden-4-yl]oxy}-5-fluorobenzonitrile

    13. 3-((1s,2s,3r)-2,3-difluoro-1-hydroxy-7-methylsulfonylindan-4-yl)oxy-5-fluoro-benzonitrile

    14. Benzonitrile, 3-(((1s,2s,3r)-2,3-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1h-inden-4-yl)oxy)-5-fluoro-

    15. Belzutifan [who-dd]

    16. Unii-7k28nb895l

    17. Belzutifan [orange Book]

    18. Chembl4585668

    19. Schembl16560918

    20. Gtpl11251

    21. Pt 2977 [who-dd]

    22. Bdbm373040

    23. Dtxsid201334517

    24. Pt 2977

    25. Ex-a4441

    26. Us9896418, Compound 289

    27. Xrc66824

    28. Nsc825217

    29. Who 11196

    30. At14994

    31. Belzutifan (pt2977, Mk-6482)

    32. Compound 2 [pmid: 31282155]

    33. Nsc-825217

    34. Mk-6482; Pt2977

    35. Ac-35183

    36. Hy-125840

    37. Cs-0101119

    38. A935088

    39. Q27456641

    40. 3-(((1s,2s,3r)-2,3-difluoro-1-hydroxy-7-(methanesulfonyl)-2,3-dihydro-1h-inden-4-yl)oxy)-5-fluorobenzonitrile

    41. 3-((1s,2s,3r)-2,3-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1h-inden-4-yloxy)-5-fluorobenzonitrile

    42. 72q

    2.4 Create Date
    2016-02-23
    3 Chemical and Physical Properties
    Molecular Weight 383.3 g/mol
    Molecular Formula C17H12F3NO4S
    XLogP32
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count8
    Rotatable Bond Count3
    Exact Mass383.04391352 g/mol
    Monoisotopic Mass383.04391352 g/mol
    Topological Polar Surface Area95.8 Ų
    Heavy Atom Count26
    Formal Charge0
    Complexity675
    Isotope Atom Count0
    Defined Atom Stereocenter Count3
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Belzutifan is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), who do not require immediate surgery.

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Belzutifan exerts its therapeutic effects by inhibiting a transcription factor necessary for the growth of solid tumors associated with VHL disease. It is taken once daily at approximately the same time each day, with or without food. Both severe anemia and hypoxia have been observed following therapy with belzutifan, and patients should be monitored closely before and during therapy to ensure patients can be managed as clinically indicated. There are no data regarding the use of erythropoiesis-stimulating agents for the treatment of belzutifan-induced anemia, and as such these therapies should be avoided. Belzutifan may cause embryo-fetal toxicity when administered to pregnant women. Female patients and male patients with female partners of reproductive potential should ensure that an effective form of contraception is used throughout therapy and for one week after the last dose - as belzutifan appears to decrease the efficacy of systemic hormonal contraceptives, patients should be advised to use an additional method of contraception (e.g. condoms) to eliminate the possibility of pregnancy during therapy.

    5.2 MeSH Pharmacological Classification

    Antineoplastic Agents

    Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)

    5.3 ATC Code

    L - Antineoplastic and immunomodulating agents

    L01 - Antineoplastic agents

    L01X - Other antineoplastic agents

    L01XX - Other antineoplastic agents

    L01XX74 - Belzutifan

    5.4 Absorption, Distribution and Excretion

    Absorption

    In patients with VHL disease-associated renal cell carcinoma, the mean Cmax and AUC0-24h at steady-state - which was achieved after approximately three days of therapy - were 1.3 g/mL and 16.7 ghr/mL, respectively. The median Tmax is one to two hours following oral administration. The administration of belzutifan with food has a negligible effect on drug disposition - when given alongside a high-calorie, high-fat meal, the Tmax was delayed by approximately 2 hours with no other clinically meaningful effects observed.

    Volume of Distribution

    The steady-state volume of distribution of belzutifan following oral administration is approximately 130 L.

    Clearance

    The mean clearance of belzutifan following oral administration is 7.3 L/h.

    5.5 Metabolism/Metabolites

    Belzutifan is primarily metabolized by UGT2B17 and CYP2C19, and to a lesser extent by CYP3A4.

    5.6 Biological Half-Life

    The mean elimination half-life of belzutifan is 14 hours.

    5.7 Mechanism of Action

    Hypoxia-inducible factor 2 (HIF-2) is a transcription factor which aids in oxygen sensing by regulating genes that promote adaptation to hypoxia. In healthy patients, when oxygen levels are normal, HIF-2 is broken down via ubiquitin-proteasomal degradation by von-Hippel Lindau (VHL) proteins. In the presence of hypoxia, HIF-2 translocates into cell nuclei and forms a transcriptional complex with hypoxia-inducible factor 1 (HIF-1) - this complex then induces the expression of downstream genes associated with cellular proliferation and angiogenesis. Patients with von-Hippel Lindau (VHL) disease lack functional VHL proteins, leading to an accumulation of HIF-2, and this accumulation is what drives the growth of VHL-associated tumors. Belzutifan is an inhibitor of HIF-2 that prevents its complexation with HIF-1 in conditions of hypoxia or impaired VHL protein function, thereby reducing the expression of HIF-2 target genes and slowing/stopping the growth of VHL-associated tumors.

    API SUPPLIERS

    read-more
    read-more

    01

    TAPI Technology & API Services

    Israel

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    World ADC London
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Contact Supplier Contact Supplier
    Flag Israel
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    TAPI Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    MSN Laboratories

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    PharmaVenue
    Not Confirmed
    arrow
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    ABOUT THIS PAGE

    Belzutifan Manufacturers

    A Belzutifan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Belzutifan, including repackagers and relabelers. The FDA regulates Belzutifan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Belzutifan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of Belzutifan manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

    Belzutifan Suppliers

    A Belzutifan supplier is an individual or a company that provides Belzutifan active pharmaceutical ingredient (API) or Belzutifan finished formulations upon request. The Belzutifan suppliers may include Belzutifan API manufacturers, exporters, distributors and traders.

    click here to find a list of Belzutifan suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

    Belzutifan GMP

    Belzutifan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Belzutifan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Belzutifan GMP manufacturer or Belzutifan GMP API supplier for your needs.

    Belzutifan CoA

    A Belzutifan CoA (Certificate of Analysis) is a formal document that attests to Belzutifan's compliance with Belzutifan specifications and serves as a tool for batch-level quality control.

    Belzutifan CoA mostly includes findings from lab analyses of a specific batch. For each Belzutifan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Belzutifan may be tested according to a variety of international standards, such as European Pharmacopoeia (Belzutifan EP), Belzutifan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Belzutifan USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search